Valérie Taly's Biography

Valérie Taly, CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité

V. Taly is a CNRS research director and group leader of the Translational Research And Microfluidics team within the clinical oncology research unit MEPPOT (personalized medicine pharmacogenomics and therapeutic optimization) in the Cordeliers Research Center (university Paris Cité). Her team performs interdisciplinary researches aiming at developing and validating microfluidic tools for cancer research in close collaboration with clinicians and researchers in oncology and toxicology. Since 2008, she developed droplet-based digital procedures for Cancer diagnosis. Recently, her research has been dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She is co-founder of EMULSEO (2018) and METHYS DX (2021) start up companies.

From Droplet-based Microfluidics Developments to Droplet-based Digital PCR

Monday, 13 December 2021 at 16:00

Add to Calendar ▼2021-12-14 09:00:002021-12-14 10:00:00Europe/LondonDroplet based Digital PCR For Patient Follow-Up: Applications to Cancer and COVID-19Lab-on-a-Chip and Microfluidics 2021 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Droplet-based microfluidics has led to the development of highly powerful systems that represent a new paradigm in High-Throughput Screening where individual assays are compartmentalized within microdroplet microreactors. The integration of such systems for series of complex individual operations on droplets has offered a solution to the necessary miniaturization and automation of individual biological assays. By combining a decrease of assay volume and an increase of throughput, this technology goes beyond the capacities of conventional screening systems. We will show how by combining droplet-based microfluidic systems and clinical advances in molecular diagnostic we have developed an original method to perform millions of single molecule PCR in parallel to detect and quantify a minority of mutant sequences within a high quantity of non-mutated sequences in complex mixture of DNA with a sensitivity and precision that was unreachable by conventional procedures.

Droplet based Digital PCR For Patient Follow-Up: Applications to Cancer and COVID-19

Tuesday, 14 December 2021 at 09:00

Technological innovations such as droplet-based digital PCR has been instrumental in the recent developments the applications of liquid biopsy to cancer patient follow-up. First, developments and validations of ddPCR based strategies for digestive cancer patients follow-up will be presented. Applicability of these strategies to covid-19 will also be examplified.

Add to Calendar ▼2021-12-13 00:00:002021-12-15 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics 2021Lab-on-a-Chip and Microfluidics 2021 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors